Phase IIb Pivotal Clinical Study Of P2B001 For The Treatment Of Early Stage Parkinson's Disease
Saturday, July 4, 2015 - 16:10
in Health & Medicine
The Phase IIb pivotal study of P2B001 for the treatment of early stage Parkinson's Disease has been announced as a success. P2B001 is a combination of low dose pramipexole and low dose rasagiline administered as a proprietary sustained release formulation. The study, titled A Phase IIb, Twelve Week, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study, To Determine the Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects with Early Parkinson's Disease, showed that it met primary and secondary clinical endpoints for both dose combinations. Specifically, the results showed: read more